Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734495 · ClinicalTrials.gov registry record · Phase 2
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
A Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT05734495 is a Phase 2 study of Waldenstrom Macroglobulinemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 42 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05734495, a Phase 2 study of Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) * Venetoclax (a BCL2 inhibitor)
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Pirtobrutinib
Study Locations (2)
Massachusetts
- Beth Israel Deaconness Medical - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2033-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05734495
The ClinicalTrials.gov registry entry for NCT05734495 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (91% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT05734495 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05734495 about?
NCT05734495 is a clinical study titled "Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia". This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinas...
What is the current status of trial NCT05734495?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2023-05-02. Estimated completion is 2033-01-25.
What conditions does trial NCT05734495 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT05734495?
The interventions under investigation include: Venetoclax (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT05734495?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734495 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.